Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2014

01-06-2014 | Clinical Study

Pediatric posterior fossa ganglioglioma: unique MRI features and correlation with BRAF V600E mutation status

Authors: Aaron J. Lindsay, Sarah Z. Rush, Laura Z. Fenton

Published in: Journal of Neuro-Oncology | Issue 2/2014

Login to get access

Abstract

Ganglioglioma (GG) is a rare pediatric brain tumor (1–4 %) with neoplastic glial and neuronal cells. Posterior fossa GGs (PF GGs) occur less frequently than supratentorial GGs (ST GGs). The BRAF V600E mutation has been reported in GGs and carries therapeutic implications. We compare the presenting symptoms, magnetic resonance imaging, BRAF V600E mutation status, treatment, and prognosis in children with ST and PF GGs. The neuro-oncology database at a tertiary care Children’s Hospital was retrospectively reviewed from 1995 to 2010 for patients with ST and PF GG. All available imaging was reviewed. Symptoms, BRAF V600E mutation status, treatment, and survival data were collected from the electronic medical record and analyzed. Our series consisted of 11 PF GG and 20 ST GG. Children with PF GG presented with ataxia, cranial nerve deficits and long tract signs whereas the majority with ST GGs presented with seizures. On imaging, PF GGs were infiltrative and expansile solid masses with dorsal predominant “paintbrush” enhancement whereas ST GGs were well circumscribed mixed solid and cystic masses with heterogeneous enhancement. Five of 11 (45 %) PF GGs and 6 of 9 (67 %) ST GGs expressed the BRAF V600E mutation. No unique imaging features were identified in BRAF V600E mutation positive tumors. The majority of ST GGs were treated with surgery alone, whereas the majority of PF GGs required multimodality therapy. PF GGs had worse progression-free survival and a higher mortality rate compared with ST GGs. Unlike ST GGs, PF GGs are expansile, infiltrative, show dorsal predominant “paintbrush” enhancement, are not amenable to gross total resection, and have worse progression-free survival and mortality.
Literature
2.
go back to reference Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109PubMedCentralPubMedCrossRef Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109PubMedCentralPubMedCrossRef
3.
go back to reference Louis DN, Wiestler OD, Ohgaki H, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon Louis DN, Wiestler OD, Ohgaki H, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon
4.
go back to reference DeMarchi R, Abu-Abed S, Munoz D, Loch Macdonald R (2011) Malignant ganglioglioma: case report and review of literature. J Neurooncol 101(2):311–318PubMedCrossRef DeMarchi R, Abu-Abed S, Munoz D, Loch Macdonald R (2011) Malignant ganglioglioma: case report and review of literature. J Neurooncol 101(2):311–318PubMedCrossRef
5.
go back to reference Im S-H, Chung CK, Cho B-K, Wang K-C, Yu I-K, Song IC, Cheon GJ, Lee DS, Kim N-R, Chi JG (2002) Intracranial ganglioglioma: preoperative characteristics and oncologic outcome after surgery. J Neurooncol 59(2):173–183PubMedCrossRef Im S-H, Chung CK, Cho B-K, Wang K-C, Yu I-K, Song IC, Cheon GJ, Lee DS, Kim N-R, Chi JG (2002) Intracranial ganglioglioma: preoperative characteristics and oncologic outcome after surgery. J Neurooncol 59(2):173–183PubMedCrossRef
6.
go back to reference Luyken C, Blumcke I, Fimmers R, Urbach H, Wiestler OD, Schramm J (2004) Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 101(1):146–155PubMedCrossRef Luyken C, Blumcke I, Fimmers R, Urbach H, Wiestler OD, Schramm J (2004) Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 101(1):146–155PubMedCrossRef
7.
go back to reference Rumana CS, Valadka AB (1998) Radiation therapy and malignant degeneration of benign supratentorial gangliogliomas. Neurosurgery 42(5):1038–1043PubMedCrossRef Rumana CS, Valadka AB (1998) Radiation therapy and malignant degeneration of benign supratentorial gangliogliomas. Neurosurgery 42(5):1038–1043PubMedCrossRef
9.
go back to reference Lagares A, Gomez PA, Lobato RD, Ricoy JR, Ramos A, de la Lama A (2001) Ganglioglioma of the brainstem: report of three cases and review of the literature. Surg Neurol 56(5):315–322; discussion 314–322 Lagares A, Gomez PA, Lobato RD, Ricoy JR, Ramos A, de la Lama A (2001) Ganglioglioma of the brainstem: report of three cases and review of the literature. Surg Neurol 56(5):315–322; discussion 314–322
10.
go back to reference Park YS, Kim D-S, Shim K-W, Kim J-H, Choi J-U (2008) Factors contributing to resectability and seizure outcomes in 44 patients with ganglioglioma. Clin Neurol Neurosurg 110(7):667–673PubMedCrossRef Park YS, Kim D-S, Shim K-W, Kim J-H, Choi J-U (2008) Factors contributing to resectability and seizure outcomes in 44 patients with ganglioglioma. Clin Neurol Neurosurg 110(7):667–673PubMedCrossRef
11.
go back to reference Baussard B, Di Rocco F, Garnett MR, Boddaert N, Lellouch-Tubiana A, Grill J, Puget S, Roujeau T, Zerah M, Sainte-Rose C (2007) Pediatric infratentorial gangliogliomas: a retrospective series. J Neurosurg 107(4 Suppl):286–291PubMedCrossRef Baussard B, Di Rocco F, Garnett MR, Boddaert N, Lellouch-Tubiana A, Grill J, Puget S, Roujeau T, Zerah M, Sainte-Rose C (2007) Pediatric infratentorial gangliogliomas: a retrospective series. J Neurosurg 107(4 Suppl):286–291PubMedCrossRef
13.
go back to reference Zentner J, Wolf HK, Ostertun B, Hufnagel A, Campos MG, Solymosi L, Schramm J (1994) Gangliogliomas: clinical, radiological, and histopathological findings in 51 patients. J Neurol Neurosurg Psychiatry 57(12):1497–1502PubMedCentralPubMedCrossRef Zentner J, Wolf HK, Ostertun B, Hufnagel A, Campos MG, Solymosi L, Schramm J (1994) Gangliogliomas: clinical, radiological, and histopathological findings in 51 patients. J Neurol Neurosurg Psychiatry 57(12):1497–1502PubMedCentralPubMedCrossRef
14.
go back to reference Chan MH, Kleinschmidt-Demasters BK, Donson AM, Birks DK, Foreman NK, Rush SZ (2012) Pediatric brainstem gangliogliomas show overexpression of neuropeptide prepronociceptin (PNOC) by microarray and immunohistochemistry. Pediatr Blood Cancer 59(7):1173–1179PubMedCrossRef Chan MH, Kleinschmidt-Demasters BK, Donson AM, Birks DK, Foreman NK, Rush SZ (2012) Pediatric brainstem gangliogliomas show overexpression of neuropeptide prepronociceptin (PNOC) by microarray and immunohistochemistry. Pediatr Blood Cancer 59(7):1173–1179PubMedCrossRef
16.
go back to reference Michaloglou C, Vredeveld LCW, Mooi WJ, Peeper DS (2008) BRAF(E600) in benign and malignant human tumours. Oncogene 27(7):877–895PubMedCrossRef Michaloglou C, Vredeveld LCW, Mooi WJ, Peeper DS (2008) BRAF(E600) in benign and malignant human tumours. Oncogene 27(7):877–895PubMedCrossRef
17.
go back to reference Sullivan RJ, Flaherty KT (2011) BRAF in melanoma: pathogenesis, diagnosis, inhibition, and resistance. J Skin Cancer 2011:423239 Sullivan RJ, Flaherty KT (2011) BRAF in melanoma: pathogenesis, diagnosis, inhibition, and resistance. J Skin Cancer 2011:423239
18.
go back to reference Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954PubMedCrossRef Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954PubMedCrossRef
20.
go back to reference Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R (2004) Mechanism of activation of the RAF–ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6):855–867PubMedCrossRef Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R (2004) Mechanism of activation of the RAF–ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6):855–867PubMedCrossRef
21.
go back to reference Chappe C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, Mercurio S, Fina F, Lena G, Colin C, Figarella-Branger D (2013) Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol 23(5):574–583. doi:10.1111/bpa.12048 PubMedCrossRef Chappe C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, Mercurio S, Fina F, Lena G, Colin C, Figarella-Branger D (2013) Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol 23(5):574–583. doi:10.​1111/​bpa.​12048 PubMedCrossRef
23.
go back to reference Donson AM, Kleinschmidt-Demasters BK, Aisner DL, Bemis LT, Birks DK, Levy JM, Smith AA, Handler MH, Foreman NK, Rush SZ Pediatric brainstem gangliogliomas show BRAF mutation in a high percentage of cases. Brain Pathol. doi:10.1111/bpa.12103 Donson AM, Kleinschmidt-Demasters BK, Aisner DL, Bemis LT, Birks DK, Levy JM, Smith AA, Handler MH, Foreman NK, Rush SZ Pediatric brainstem gangliogliomas show BRAF mutation in a high percentage of cases. Brain Pathol. doi:10.​1111/​bpa.​12103
24.
go back to reference Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, Storm PB, Biegel JA (2010) Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neurooncology 12(7):621–630 Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, Storm PB, Biegel JA (2010) Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neurooncology 12(7):621–630
25.
go back to reference Koelsche C, Wohrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, Lasitschka F, von Deimling A, Capper D Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 125(6):891–900. doi:10.1007/s00401-013-1100-2 Koelsche C, Wohrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, Lasitschka F, von Deimling A, Capper D Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 125(6):891–900. doi:10.​1007/​s00401-013-1100-2
26.
go back to reference MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, Garraway LA (2009) Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 4(11):e7887. doi:10.1371/journal.pone.0007887 PubMedCentralPubMedCrossRef MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, Garraway LA (2009) Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 4(11):e7887. doi:10.​1371/​journal.​pone.​0007887 PubMedCentralPubMedCrossRef
27.
go back to reference Myung JK, Cho H, Park CK, Kim SK, Lee SH, Park SH (2012) Analysis of the BRAF(V600E) mutation in central nervous system tumors. Transl Oncol 5(6):430–436PubMedCentralPubMedCrossRef Myung JK, Cho H, Park CK, Kim SK, Lee SH, Park SH (2012) Analysis of the BRAF(V600E) mutation in central nervous system tumors. Transl Oncol 5(6):430–436PubMedCentralPubMedCrossRef
28.
go back to reference Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397–405PubMedCrossRef Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397–405PubMedCrossRef
30.
go back to reference Johnson JH, Hariharan S, Berman J, Sutton LN, Rorke LB, Molloy P, Phillips PC (1997) Clinical outcome of pediatric gangliogliomas: ninety-nine cases over 20 years. Pediatr Neurosurg 27(4):203–207PubMedCrossRef Johnson JH, Hariharan S, Berman J, Sutton LN, Rorke LB, Molloy P, Phillips PC (1997) Clinical outcome of pediatric gangliogliomas: ninety-nine cases over 20 years. Pediatr Neurosurg 27(4):203–207PubMedCrossRef
32.
go back to reference Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D, Bastian BC (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95(24):1878–1890PubMedCrossRef Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D, Bastian BC (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95(24):1878–1890PubMedCrossRef
33.
go back to reference Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H, Youn YK (2012) BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 36(2):310–317. doi:10.1007/s00268-011-1383-1 PubMedCrossRef Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H, Youn YK (2012) BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 36(2):310–317. doi:10.​1007/​s00268-011-1383-1 PubMedCrossRef
34.
go back to reference Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park do J (2012) The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118(7):1764–1773. doi:10.1002/cncr.26500 PubMedCrossRef Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park do J (2012) The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118(7):1764–1773. doi:10.​1002/​cncr.​26500 PubMedCrossRef
35.
go back to reference Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M (2012) BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltim) 91(5):274–286. doi:10.1097/MD.0b013e31826a9c71 CrossRef Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M (2012) BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltim) 91(5):274–286. doi:10.​1097/​MD.​0b013e31826a9c71​ CrossRef
36.
go back to reference Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, Waldman TA, James CD (2011) Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 17(24):7595–7604. doi:10.1158/1078-0432.CCR-11-1456 PubMedCentralPubMedCrossRef Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, Waldman TA, James CD (2011) Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 17(24):7595–7604. doi:10.​1158/​1078-0432.​CCR-11-1456 PubMedCentralPubMedCrossRef
37.
go back to reference Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley M-YC, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD (2010) Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70(2):512–519PubMedCentralPubMedCrossRef Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley M-YC, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD (2010) Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70(2):512–519PubMedCentralPubMedCrossRef
Metadata
Title
Pediatric posterior fossa ganglioglioma: unique MRI features and correlation with BRAF V600E mutation status
Authors
Aaron J. Lindsay
Sarah Z. Rush
Laura Z. Fenton
Publication date
01-06-2014
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-014-1450-1

Other articles of this Issue 2/2014

Journal of Neuro-Oncology 2/2014 Go to the issue